医疗观察：美国食品药品监督管理局的医疗产品报告计划。 - Suppr

Suppr

超能文献

MedWatch: FDA's Medical Products Reporting Program.

作者信息

Goldman S A, Kennedy D L

出版信息

Postgrad Med. 1998 Mar;103(3):13-6. doi: 10.3810/pgm.1998.03.408.

DOI:10.3810/pgm.1998.03.408

PMID:9519028

Abstract

摘要

相似文献

MedWatch: FDA's Medical Products Reporting Program.

Postgrad Med. 1998 Mar;103(3):13-6. doi: 10.3810/pgm.1998.03.408.

MedWatch. FDA's 'heads up' on medical product safety.

FDA Consum. 1998 Nov-Dec;32(6):10-2, 15.

MedWatch: FDA's new medical products reporting program.

J Clin Eng. 1993 Nov-Dec;18(6):489-92. doi: 10.1097/00004669-199311000-00009.

MEDWatch: the new FDA medical products reporting program.

Am J Hosp Pharm. 1993 Jun;50(6):1151-2.

MedWatch: the FDA medical products reporting program.

Am Fam Physician. 1993 Sep 15;48(4):636-8.

MedWatch: the new medical products reporting program.

Am J Nurs. 1993 Aug;93(8):65-8.

A one-year perspective on MedWatch: the Food and Drug Administration's new medical products reporting program.

J Allergy Clin Immunol. 1995 Jun;95(6):1153-7. doi: 10.1016/s0091-6749(95)70070-6.

The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.

Clin Pharmacol Ther. 2016 Mar;99(3):265-8. doi: 10.1002/cpt.320. Epub 2016 Jan 12.

FDA's monitoring of postmarketing studies probed.

Am J Health Syst Pharm. 2006 Aug 15;63(16):1485-6. doi: 10.2146/news060003.

Food and Drug Administration update. The MedWatch program.

J Toxicol Clin Toxicol. 1998;36(1-2):145-9. doi: 10.3109/15563659809162609.

引用本文的文献

Developing a Method for Reporting Patient Harm Due to Antimicrobial Shortages.

Infect Dis Ther. 2014 Dec;3(2):349-55. doi: 10.1007/s40121-014-0040-z. Epub 2014 Sep 19.

Legal regulations of complementary and alternative medicines in different countries.

Pharmacogn Rev. 2012 Jul;6(12):154-60. doi: 10.4103/0973-7847.99950.

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Am J Cardiovasc Drugs. 2008;8(6):373-418. doi: 10.2165/0129784-200808060-00004.

Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

Drug Saf. 2007;30(8):669-75. doi: 10.2165/00002018-200730080-00003.

Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Drug Saf. 2001;24(9):637-43. doi: 10.2165/00002018-200124090-00001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验